Prioritization of candidate cancer genes-an aid to oncogenomic studies

The development of techniques for oncogenomic analyses such as array comparative genomic hybridization, messenger RNA expression arrays and mutational screens have come to the fore in modern cancer research. Studies utilizing these techniques are able to highlight panels of genes that are altered in cancer. However, these candidate cancer genes must then be scrutinized to reveal whether they contribute to oncogenesis or are coincidental and non-causative. We present a computational method for the prioritization of candidate (i) proto-oncogenes and (ii) tumour suppressor genes from oncogenomic experiments. We constructed computational classifiers using different combinations of sequence and functional data including sequence conservation, protein domains and interactions, and regulatory data. We found that these classifiers are able to distinguish between known cancer genes and other human genes. Furthermore, the classifiers also discriminate candidate cancer genes from a recent mutational screen from other human genes. We provide a web-based facility through which cancer biologists may access our results and we propose computational cancer gene classification as a useful method of prioritizing candidate cancer genes identified in oncogenomic studies.

Copia de una carta remitida por el obispo Mateo Múgica al Presidente del Gobierno Vasco en el exilio.

Fecha: 19-3-1946 (>1970 copia) / Unidad de instalación: Carpeta 45 - Expediente 2-24 / Nº de pág.: 3 (mecanografiadas)

Cartas enviadas por Antonio Asa a Justo Garate en 1942

2 cartas (manuscritas) ; entre 220x140mm y 210x275mm. Ubicación: Caja 1 - Carpeta 69

Transcripción de la conversación por teletipo mantenida por el Presidente de Euzkadi y los militares republicanos Belarmino Tomás y Francisco Ciutat sobre diversos aspectos de la campaña del Norte

Sin fecha (1937)/ Unidad de ínstalación: Carpeta Rectorado - B-2 / Nº de hojas: 2. Mecanografiado

Transcripción de la conversación por teletipo entre el Presidente de Euzkadi y Francisco Ciutat con relación al estado de la guerra

Sin fecha (1937) / Unidad de ínstalación: Carpeta Rectorado - B-3 / Nº de pág.: 1 (mecanografiada)

Transcripción de la conversación por teletipo entre los militares republicanos Belarmino Tomás y Francisco Ciutat con el Presidente de Euzkadi con relación a noticias sobre el frente

Sin fecha (1937) / Unidad de ínstalación: Carpeta Rectorado - B-4 / Nº de pág.: 1. Mecanografiada

Transcripción de la conversación con teletipo entre Francisco Ciutat y el Presidente de Euzkadi con relación al estado de la Guerra Civil

Sin fecha (1937) / Unidad de ínstalación: Carpeta Rectorado - B-5 y 6 / Nº de pág.: 1 (escrita por las dos caras). Mecanografiada

Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness

Lymphangioleiomyomatosis (LAM) is a rare lung-metastasizing neoplasm caused by the proliferation of smooth muscle-like cells that commonly carry loss-of-function mutations in either the tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) genes. While allosteric inhibition of the mechanistic target of rapamycin (mTOR) has shown substantial clinical benefit, complementary therapies are required to improve response and/or to treat specific patients. However, there is a lack of LAM biomarkers that could potentially be used to monitor the disease and to develop other targeted therapies. We hypothesized that the mediators of cancer metastasis to lung, particularly in breast cancer, also play a relevant role in LAM. Analyses across independent breast cancer datasets revealed associations between low TSC1/2 expression, altered mTOR complex 1 (mTORC1) pathway signaling, and metastasis to lung. Subsequently, immunohistochemical analyses of 23 LAM lesions revealed positivity in all cases for the lung metastasis mediators fascin 1 (FSCN1) and inhibitor of DNA binding 1 (ID1). Moreover, assessment of breast cancer stem or luminal progenitor cell biomarkers showed positivity in most LAM tissue for the aldehyde dehydrogenase 1 (ALDH1), integrin-beta 3 (ITGB3/CD61), and/or the sex-determining region Y-box 9 (SOX9) proteins. The immunohistochemical analyses also provided evidence of heterogeneity between and within LAM cases. The analysis of Tsc2-deficient cells revealed relative over-expression of FSCN1 and ID1; however, Tsc2-deficient cells did not show higher sensitivity to ID1-based cancer inhibitors. Collectively, the results of this study reveal novel LAM biomarkers linked to breast cancer metastasis to lung and to cell stemness, which in turn might guide the assessment of additional or complementary therapeutic opportunities for LAM.